# Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2023

- Company: [Amneal Pharmaceuticals, Inc.](/companies/amrx.md) (CIK 1723128)
- Form: 10-Q
- Filed: 2023-11-09
- Accepted by EDGAR: Nov 8, 2023, 18:51 ET
- Period: 2023-09-30
- Accession: 0001723128-23-000044
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000044/amrx-20230930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000044/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-07-01 to 2023-09-30 | $620.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2023-01-01 to 2023-09-30 | $1.78bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-07-01 to 2023-09-30 | $387.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2023-01-01 to 2023-09-30 | $1.15bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2023-07-01 to 2023-09-30 | $232.5m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2023-01-01 to 2023-09-30 | $630.7m | us-gaap:GrossProfit |
| Research and development | 3 months, 2023-07-01 to 2023-09-30 | $41.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2023-01-01 to 2023-09-30 | $117.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2023-07-01 to 2023-09-30 | $113.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2023-01-01 to 2023-09-30 | $320.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2023-07-01 to 2023-09-30 | $75.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2023-01-01 to 2023-09-30 | $190.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2023-07-01 to 2023-09-30 | −$2.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2023-01-01 to 2023-09-30 | −$1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-07-01 to 2023-09-30 | $15.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-01-01 to 2023-09-30 | $22.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-07-01 to 2023-09-30 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2023-01-01 to 2023-09-30 | $0.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-07-01 to 2023-09-30 | $0.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2023-01-01 to 2023-09-30 | $0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-07-01 to 2023-09-30 | 159,691,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-01-01 to 2023-09-30 | 156,284,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-01-01 to 2023-09-30 | $209.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2023-01-01 to 2023-09-30 | $33.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-09-30 | $86.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-09-30 | $1.46bn | us-gaap:AssetsCurrent |
| Total assets | at 2023-09-30 | $3.69bn | us-gaap:Assets |
| Current liabilities | at 2023-09-30 | $760.6m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2023-09-30 | $2.54bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2023-09-30 | $30.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2023-09-30 | $330.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 46,897 characters.

Amneal Pharmaceuticals, Inc. (the “Company”, “we,” “us,” or “our”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including complex generics and specialty branded pharmaceuticals. We operate principally in the United States (the “U.S.”), India, and Ireland, and sell to wholesalers, distributors, hospitals, chain pharmacies and individual pharmacies, either directly or indirectly. Prior to the Reorganization (as defined herein) and during the period covered by this report, we were a holding company, whose principal assets were common units (“Amneal Common Units”) of Amneal Pharmaceuticals, LLC (“Amneal”).

As of September 30, 2023, the Company held 50.4% of Amneal Common Units and the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company, held the remaining 49.6%. The Company is Amneal’s sole managing member, having the sole voting power to make all of Amneal’s business decisions and control its management. Therefore, the Company has historically consolidated the financial statements of Amneal and its subsidiaries. The Company recorded non-controlling interests for the portion of Amneal’s economic interests that it does not hold. For further information regarding the Reorganization, refer to “*Note 24. Subsequent Events —* Up-C Corporate Structure Elimination”.

The following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under Item 1A. *Risk Factors* in our 2022 Annual Report on Form 10-K and under the heading *Cautionary Note Regarding Forward-Looking Statements* included elsewhere in this Quarterly Report on Form 10-Q.

The following discussion and analysis for the three and nine months ended September 30, 2023 should also be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements for the year ended December 31, 2022 included in our 2022 Annual Report on Form 10-K.

### Overview

We have three reportable segments: Generics, Specialty, and AvKARE.

#### Generics

Our Generics segment includes approximately 260 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, films, transdermal patches and topicals. We focus on developing products with substantial barriers-to-entry resulting from complex drug formulations or manufacturing, or legal or regulatory challenges. Generic products, particularly in the U.S., generally contribute most significantly to revenues and gross margins at the time of their launch, and even more so in periods of market exclusivity, or in periods of limited generic competition. As such, the timing of new product introductions can have a significant impact on the Company’s financial results. The entrance into the market of additional competition generally has a negative impact on the volume and/or pricing of the affected products. Additionally, pricing is determined by market place dynamics and is often affected by factors outside of the Company’s control.

#### Specialty

Our Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing CNS disorders, including Parkinson’s disease, and endocrine disorders. Our portfolio of products includes Rytary®, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. In addition to Rytary®, our promoted Specialty portfolio also includes Unithroid® (levothyroxine sodium), for the treatment of hypothyroidism, which is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc., and Lyvispah® (baclofen), a unique dissolvable granule formulation used to treat muscle stiffness, spasms and pain from multiple sclerosis.

Our Specialty products are marketed through skilled specialty sales and marketing teams, who call on neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S. Our Specialty segment also has a number of product candidates that are in varying stages of development.

For Specialty products, the majority of the product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S., when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales.

On June 30, 2023, we received a complete response letter (“CRL”) from the Food and Drug Administration (“FDA”) regarding our new drug application for IPX203 for the treatment of Parkinson’s disease. The CRL indicated that although an adequate scientific bridge was established for the safety of one ingredient, levodopa, based on pharmacokinetic studies, it was not adequately established for the other ingredient, carbidopa, and the FDA requested additional information. The CRL did not identify any issues with respect to the efficacy or manufacturing of IPX203. During October 2023, we met with the FDA to align on the path to approval for IPX203. During the meeting, the FDA asked us to complete a QT study, a routine cardiac safety study that is required for new drugs. We are in the process of completing this study and expect to resubmit our new drug application for IPX203 in early 2024.

Developing and commercializing a new product is time consuming, costly and subject to numerous factors that may delay or prevent such development and commercialization. Our future results of operations will depend, to a significant extent, upon our ability to successfully commercialize new products, including IPX203. Failure to successfully commercialize IPX203 in a timely manner could negatively impact our future growth and could result in material impairment charges associated with our IPX203 in-process research and development intangible asset and our Specialty segment’s goodwill. Refer to the information under the heading “If we are unable to successfully develop or commercial new products, our operating results will suffer.” in the *Operational and Competitive Risks* section of Item 1A. Risk Factors in our 2022 Annual Report on Form 10-K for additional information associated with the risk related to FDA approval of IPX203. Refer to *Note 12. Goodwill and Other Intangible Assets* in this Form 10-Q for a discussion of interim impairment testing.

#### AvKARE

Our AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, which service the Department of Defense and Department of Veteran Affairs as well as institutional customers. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter products and medical supplies to institutional customers which are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing.

#### The Pharmaceutical Industry

The pharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. For a more detailed explanation of our business and its risks, refer to our *2022 Annual Report on Form 10-K,* as supplemented by Part II, Item 1A “Risk Factors” of our subsequent Quarterly Reports on Form 10-Q.

#### Inflation

While it is difficult to accurately measure the impact of inflation, we estimate our business will experience an increase in costs due to inflation of approximately $15.0 million for the year ending December 31, 2023, excluding the impact of rising interest rates. However, rising inflationary pressures due to higher input costs, including higher material, transportation, labor and other costs, could exceed our expectations, which would further adversely impact our operating results in future periods.

### Results of Operations

### Comparison of Three Months Ended September 30, 2023 to Three Months Ended September 30, 2022

### Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the three months ended September 30, 2023 and 2022 (in thousands):

|  | Three Months Ended September 30, 2023 | 2022 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $620,040 | $545,557 | $74,483 | 13.7% |
| Cost of goods sold | 387,509 | 351,327 | 36,182 | 10.3% |
| **Gross profit** | 232,531 | 194,230 | 38,301 | 19.7% |
| Selling, general and administrative | 113,006 | 100,071 | 12,935 | 12.9% |
| Research and development | 41,375 | 50,235 | (8,860) | (17.6)% |
| Intellectual property legal development expenses | 886 | 1,411 | (525) | (37.2)% |
| Acquisition, transaction-related and integration expenses | — | 39 | (39) | (100.0)% |
| Restructuring and other charges | 1,043 | 581 | 462 | 79.5% |
| Change in fair value of contingent consideration | 3,120 | (1,425) | 4,545 | nm |
| (Credit) charges related to legal matters, net | (2,620) | 285 | (2,905) | nm |
| Other operating expense (income) | 73 | (1,320) | 1,393 | (105.5)% |
| **Operating income** | 75,648 | 44,353 | 31,295 | 70.6% |
| Total other expense, net | (52,691) | (42,173) | (10,518) | 24.9% |
| Income before income taxes | 22,957 | 2,180 | 20,777 | nm |
| (Benefit from) provision for income taxes | (2,076) | 4,570 | (6,646) | nm |
| **Net income (loss)** | $25,033 | $(2,390) | $27,423 | nm |

nm - not meaningful

#### Net Revenue

Net revenue for the three months ended September 30, 2023 increased 13.7% from the prior year period primarily due to:

- Growth in our Generics segment of $40.6 million, primarily due to new generics products launched in 2023 and 2022, which includes biosimilars that contributed $25.0 million and new generic products that contributed $15.0 million, and strong volume growth, partially offset by continued price erosion.
- Growth in our AvKARE segment of $26.1 million, due to growth in our distribution and government label channels driven by new product introductions.
- Growth in our Specialty segment of $7.8 million driven by growth in Unithroid® of 31.9%, partially offset by a 5.2% decline in Rytary® driven by Medicare rebates associated with the Inflation Reduction Act of approximately $5.5 million. Excluding these rebates, Rytary® net revenue grew 6.5%.

#### Cost of Goods Sold and Gross Profit

Cost of goods sold increased 10.3% for the three months ended September 30, 2023 as compared to the prior year period. The increase in cost of goods sold was primarily due to increased volume across our Generics and AvKARE segments, increased inventory provision and product mix.

Gross profit as a percentage of net revenue increased to 37.5% for the three months ended September 30, 2023 from 35.6% in the prior year period primarily as a result of the factors noted above.

#### Selling, General, and Administrative

Selling, general, and administrative (“SG&A”) expenses for the three months ended September 30, 2023 increased 12.9% from the prior year period primarily due to increases in employee compensation, higher legal fees and increased promotional spending.

#### Research and Development

Research and development (“R&D”) expenses for the three months ended September 30, 2023 decreased 17.6% compared to the prior year period primarily due to lower project spend of $4.8 million partially resulting from timing of regulatory filing fees, a decrease in in-licensing and upfront milestone payments of $1.5 million and operating efficiencies in our infrastructure.

#### Change in Fair Value of Contingent Consideration

Refer to *Note 17. Fair Value Measurements* for information about the estimation of our contingent consideration liabilities. The $4.5 million increase in the change in fair value of contingent consideration for the three months ended September 30, 2023 as compared to the prior year period was primarily driven by a decrease in the cost of debt in the current period and revision of forecasted revenues.

#### (Credit) Charges Related to Legal Matters, Net

For the three months ended September 30, 2023, credit related to legal matters, net of $2.6 million primarily related to a $5.5 million gain from the settlement of patent infringement matters, partially offset by a $3.0 million charge for the settlement of a customer claim. For the three months ended September 30, 2022, charges related to legal matters, net, were immaterial. Refer to *Note 19. Commitments and Contingencies* for additional information.

#### Total Other Expense, Net

Total other expense, net for the three months ended September 30, 2023 increased 24.9% compared to the prior year period. This increase was primarily driven by an $8.5 million increase in interest expense as a result of higher rates on our variable-rate debt and increased amounts outstanding on our revolving credit facilities.

#### (Benefit From) Provision For Income Taxes

For the three months ended September 30, 2023, the Company’s benefit from income taxes and effective tax rate were $2.1 million and (9.0)%. respectively, as compared to a provision for income taxes and effective tax rate of $4.6 million and 209.6%, respectively, for the three months ended September 30, 2022. The period-over-period change in the (benefit from) provision for income taxes was primarily related to changes in the jurisdictional mix of income and a discrete Indian tax benefit of approximately $2.9 million from the utilization of a loss carryforward after the completion of a merger of certain of our subsidiaries in India during the three months ended September 30, 2023.

### Generics

The following table sets forth results of operations for our Generics segment for the three months ended September 30, 2023 and 2022 (in thousands):

|  | Three Months Ended September 30, 2023 | 2022 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $390,857 | $350,266 | $40,591 | 11.6% |
| Cost of goods sold | 236,268 | 218,671 | 17,597 | 8.0% |
| **Gross profit** | 154,589 | 131,595 | 22,994 | 17.5% |
| Selling, general and administrative | 33,538 | 30,259 | 3,279 | 10.8% |
| Research and development | 35,103 | 41,987 | (6,884) | (16.4)% |
| Intellectual property legal development expenses | 815 | 1,369 | (554) | (40.5)% |
| Acquisition, transaction-related and integration expenses | — | 16 | (16) | (100.0)% |
| Restructuring and other charges | 112 | 507 | (395) | (77.9)% |
| (Credit) Charges related to legal matters, net | (2,500) | 285 | (2,785) | nm |
| Other operating expense (income) | 73 | (1,320) | 1,393 | nm |
| **Operating income** | $87,448 | $58,492 | $28,956 | 49.5% |

nm - not meaningful

#### Net Revenue

Generics net revenue for the three months ended September 30, 2023 increased 11.6% compared to the prior year period. Growth in our Generics segment of $40.6 million was primarily due to new generics products launched in 2023 and 2022, which includes biosimilars that contributed $25.0 million and new generic products that contributed $15.0 million, and strong volume growth, partially offset by continued price erosion.

#### Cost of Goods Sold and Gross Profit

Generics cost of goods sold for the three months ended September 30, 2023 increased 8.0% compared to the prior year period primarily due to costs associated with increased sales volume, including the launch of biosimilars, and an increased inventory provision.

Generics gross profit as a percentage of net revenue increased to 39.6% for the three months ended September 30, 2023 from 37.6% in the prior year period primarily as a result of the factors noted above.

#### Selling, General, and Administrative

Generics SG&A expense for the three months ended September 30, 2023 increased 10.8% compared to the prior year period primarily due to an increase in employee compensation, including the biosimilar sales force.

#### Research and Development

Generics R&D expenses for the three months ended September 30, 2023 decreased 16.4% compared to the prior year period primarily due to a decrease in project spend of $3.2 million partially due to the timing of regulatory filing fees and operating efficiencies in our infrastructure.

#### (Credit) Charges Related to Legal Matters, Net

For the three months ended September 30, 2023, credit related to legal matters, net of $2.5 million primarily related to a $5.5 million gain from the settlement of patent infringement matters, partially offset by a $3.0 million charge for the settlement of a customer claim. Charges related to legal matters, net for the three months ended September 30, 2022 were immaterial. Refer to *Note 19. Commitments and Contingencies* for additional information.

#### Other operating expense (income)

Other operating income for the three months ended September 30, 2022 was comprised of income earned from the India Production Linked Incentive Scheme for the Pharmaceutical Sector. Refer to *Note 6. Government Grants* for additional information.

### Specialty

The following table sets forth results of operations for our Specialty segment for the three months ended September 30, 2023 and 2022 (in thousands):

|  | Three Months Ended September 30, 2023 | 2022 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $97,304 | $89,484 | $7,820 | 8.7% |
| Cost of goods sold | 45,551 | 43,719 | 1,832 | 4.2% |
| **Gross profit** | 51,753 | 45,765 | 5,988 | 13.1% |
| Selling, general and administrative | 22,756 | 22,201 | 555 | 2.5% |
| Research and development | 6,272 | 8,248 | (1,976) | (24.0)% |
| Intellectual property legal development expenses | 71 | 42 | 29 | 69.0% |
| Acquisition, transaction-related and integration expenses | — | 15 | (15) | (100.0)% |
| Restructuring and other charges | 931 | — | 931 | nm |
| Change in fair value of contingent consideration | 3,120 | (1,425) | 4,545 | nm |
| **Operating income** | $18,603 | $16,684 | $1,919 | 11.5% |

nm - not meaningful

#### Net Revenue

Specialty net revenue for the three months ended September 30, 2023 increased 8.7% compared to the prior year period. Growth in our Specialty segment of $7.8 million was primarily driven by growth in Unithroid® of 31.9%, partially offset by a 5.2% decline in Rytary® driven by Medicare rebates associated with the Inflation Reduction Act of approximately $5.5 million. Excluding these rebates, Rytary® net revenue grew 6.5%.

#### Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the three months ended September 30, 2023 increased 4.2% compared to the prior year period. Specialty gross profit as a percentage of net revenue increased to 53.2% for the three months ended September 30, 2023 from 51.1% in the prior year period, primarily due to favorable product mix.

#### Selling, General, and Administrative

Specialty SG&A expense for the three months ended September 30, 2023 increased 2.5% compared to the prior year period primarily due to an increase in third party marketing spend and sales force expenses for our promoted products.

#### Research and Development

Specialty R&D expenses for the three months ended September 30, 2023 decreased 24.0% compared to the prior year period primarily due to reduced project spend and a decrease in in-licensing and upfront milestone charges of $2.0 million.

#### Change in Fair Value of Contingent Consideration

Refer to *Note 17. Fair Value Measurements* for information about the estimation of our contingent consideration liabilities. The $4.5 million increase in the change in fair value of contingent consideration for the three months ended September 30, 2023 as compared to the prior year period was primarily driven by a decrease in the cost of debt and an increase in forecasted revenues in the current year period.

### AvKARE

The following table sets forth results of operations for our AvKARE segment for the three months ended September 30, 2023 and 2022 (in thousands):

|  | Three Months Ended September 30, 2023 | 2022 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $131,879 | $105,807 | $26,072 | 24.6% |
| Cost of goods sold | 105,690 | 88,937 | 16,753 | 18.8% |
| **Gross profit** | 26,189 | 16,870 | 9,319 | 55.2% |
| Selling, general and administrative | 14,313 | 13,216 | 1,097 | 8.3% |
| **Operating income** | $11,876 | $3,654 | $8,222 | 225.0% |

#### Net Revenue

AvKARE net revenue for the three months ended September 30, 2023 increased 24.6% as compared to the prior year period primarily due to growth in our distribution and government channels driven by new product introductions.

#### Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the three months ended September 30, 2023 increased 18.8% as compared to the prior year period, and gross profit as a percentage of net revenue increased to 19.9% for the three months ended September 30, 2023 from 15.9% in the prior year period primarily due to the increase in sales through our higher margin government channel including higher margin new product introductions.

#### Selling, General and Administrative

AvKARE SG&A expense for the three months ended September 30, 2023 increased 8.3% as compared to the prior year period primarily due to higher employee compensation.

### Comparison of Nine Months Ended September 30, 2023 to Nine Months Ended September 30, 2022

### Consolidated Results

The following table sets forth our summarized, consolidated results of operations for the nine months ended September 30, 2023 and 2022 (in thousands):

|  | Nine Months Ended September 30, 2023 | 2022 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $1,776,626 | $1,602,545 | $174,081 | 10.9% |
| Cost of goods sold | 1,145,888 | 1,033,225 | 112,663 | 10.9% |
| **Gross profit** | 630,738 | 569,320 | 61,418 | 10.8% |
| Selling, general and administrative | 320,672 | 297,542 | 23,130 | 7.8% |
| Research and development | 117,864 | 153,781 | (35,917) | (23.4)% |
| Intellectual property legal development expenses | 3,350 | 2,996 | 354 | 11.8% |
| Acquisition, transaction-related and integration expenses | — | 714 | (714) | (100.0)% |
| Restructuring and other charges | 1,635 | 1,312 | 323 | 24.6% |
| Change in fair value of contingent consideration | (787) | (1,495) | 708 | (47.4)% |
| Insurance recoveries for property losses and associated expenses | — | (1,911) | 1,911 | (100.0)% |
| (Credit) charges related to legal matters, net | (1,039) | 249,836 | (250,875) | nm |
| Other operating income | (1,138) | (2,495) | 1,357 | (54.4)% |
| **Operating income (loss)** | 190,181 | (130,960) | 321,141 | nm |
| Total other expense, net | (146,990) | (109,512) | (37,478) | 34.2% |
| Income (loss) before income taxes | 43,191 | (240,472) | 283,663 | nm |
| (Benefit from) provision for income taxes | (1,431) | 8,459 | (9,890) | nm |
| **Net income (loss)** | $44,622 | $(248,931) | $293,553 | nm |

nm - not meaningful

#### Net Revenue

Net revenue for the nine months ended September 30, 2023 increased 10.9% from the prior year period primarily due to:

- Growth in our Generics segment of $75.5 million primarily due to new generics products launched in 2023 and 2022, which includes biosimilars that contributed $40.0 million and new generic products that contributed $35.7 million and strong volume growth, partially offset by continued price erosion. Net revenue for the nine months ended September 30, 2023 included a non-recurring customer order of $21.0 million.
- Growth in our AvKARE segment net revenue of $84.2 million, primarily driven by growth in our distribution and government label channels resulting from growth in new product introductions.
- Growth in Specialty segment net revenue of $14.4 million primarily driven by 30.7% growth in Unithroid® and a 0.8% increase in Rytary®, which was negatively impacted by Medicare rebates associated with the Inflation Reduction Act of approximately $5.5 million. Excluding these rebates, net revenues of Rytary® increased 5.0%.

#### Cost of Goods Sold and Gross Profit

Cost of goods sold increased 10.9% for the nine months ended September 30, 2023 as compared to the prior year period. The increase in cost of goods sold was primarily due to increased AvKARE and Generics volume and an increase in the inventory provision. Cost of goods sold for the nine months ended September 30, 2023 included $11.0 million associated with the non-recurring customer order in our Generics segment discussed above.

Gross profit as a percentage of net revenue was 35.5% for each of the nine months ended September 30, 2023 and 2022.

#### Selling, General, and Administrative

SG&A expenses for the nine months ended September 30, 2023 increased 7.8% from the prior year period primarily due to increases in employee compensation, higher costs associated with our biosimilar launches, increased legal fees and higher freight charges driven by increased sales volume, partially offset by a decrease of $5.0 million associated with a regulatory approval in the prior year period.

#### Research and Development

R&D expenses for the nine months ended September 30, 2023 decreased 23.4% compared to the prior year period primarily due to reduced project spend of $17.3 million, a decrease in in-licensing and upfront milestone payments of $7.1 million, and operating efficiencies in our infrastructure.

#### Insurance Recoveries for Property Losses and Associated Expenses

During the nine months ended September 30, 2022, insurance recoveries of $1.9 million associated with property damage and inventory losses were received and recorded in insurance recoveries for property losses and associated expenses. Refer to *Note 23. Insurance Recoveries for Property Losses and Associated Expenses.*

#### (Credit) Charges Related to Legal Matters, Net

For the nine months ended September 30, 2023, credit related to legal matters, net was $1.0 million, primarily comprised of $10.0 million from the settlement of patent infringement matters, partially offset by $4.1 million in charges associated with civil prescription opioid litigation, a $3.0 million charge for the settlement of a customer claim, and a $1.9 million charge for the settlement of a stockholder derivative lawsuit. For the nine months ended September 30, 2022, we recorded a net charge of $249.8 million, primarily comprised of a charge associated with Opana® ER antitrust litigation, net of insurance recoveries associated with a securities class action settled during 2022. Refer to *Note 19. Commitments and Contingencies* for additional information.

#### Other Operating Income

Other operating income for the nine months ended September 30, 2023 and 2022 was comprised of income earned from the India Production Linked Incentive Scheme for the Pharmaceutical Sector. Refer to *Note 6. Government Grants* for additional information.

#### Total Other Expense, Net

Total other expense, net for the nine months ended September 30, 2023 increased 34.2% as compared to the prior year period. The increase was primarily driven by a $39.7 million increase in interest expense as a result of higher rates on our variable-rate debt and increased amounts outstanding on our revolving credit facilities.

#### (Benefit From) Provision For Income Taxes

For the nine months ended September 30, 2023, our benefit from income taxes and effective tax rate were $(1.4) million and (3.3)%, respectively, as compared to a provision for income taxes of $8.5 million and an effective tax rate of (3.5)% for the nine months ended September 30, 2022. The period-over-period change in the (benefit from) provision for income taxes was primarily related to changes in the jurisdictional mix of income and a discrete Indian tax benefit of $2.9 million from the utilization of a loss carryforward after the completion of a merger of certain of our subsidiaries in India during the three months ended September 30, 2023.

### Generics

The following table sets forth results of operations for our Generics segment for the nine months ended September 30, 2023 and 2022 (in thousands):

|  | Nine Months Ended September 30, 2023 | 2022 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $1,108,364 | $1,032,908 | $75,456 | 7.3% |
| Cost of goods sold | 692,008 | 646,236 | 45,772 | 7.1% |
| **Gross profit** | 416,356 | 386,672 | 29,684 | 7.7% |
| Selling, general and administrative | 89,178 | 84,410 | 4,768 | 5.6% |
| Research and development | 98,570 | 129,382 | (30,812) | (23.8)% |
| Intellectual property legal development expenses | 3,240 | 2,919 | 321 | 11.0% |
| Acquisition, transaction-related and integration expenses | — | 24 | (24) | (100.0)% |
| Restructuring and other charges | 211 | 713 | (502) | (70.4)% |
| Insurance recoveries for property losses and associated expenses | — | (1,911) | 1,911 | (100.0)% |
| (Credit) charges related to legal matters, net | (2,927) | 2,442 | (5,369) | nm |
| Other operating income | (1,138) | (2,495) | 1,357 | (54.4)% |
| **Operating income** | $229,222 | $171,188 | $58,034 | 33.9% |

#### Net Revenue

Generics net revenue for the nine months ended September 30, 2023 increased 7.3% compared to the prior year period primarily due to new generic products launched in 2023 and 2022, which includes biosimilars that contributed $40.0 million and new generic products that contributed $35.7 million and strong volume growth, partially offset by continued price erosion. Net revenue for the nine months ended September 30, 2023 included a non-recurring customer order of $21.0 million.

#### Cost of Goods Sold and Gross Profit

Generics cost of goods sold for the nine months ended September 30, 2023 increased 7.1% as compared to the prior year period primarily due to costs associated with increased sales volume and an increased inventory provision. Cost of goods sold for the nine months ended September 30, 2023 included $11.0 million associated with the non-recurring customer order discussed above.

Generics gross profit as a percentage of net revenue increased to 37.6% for the nine months ended September 30, 2023 from 37.4% in the prior year period primarily as a result of the factors noted above.

#### Selling, General, and Administrative

Generics SG&A expense for the nine months ended September 30, 2023 increased 5.6% compared to the prior year period primarily due to an increase in employee compensation, higher freight charges driven by increased sales volume and costs associated with our biosimilar launches, partially offset by a decrease of $5.0 million associated with a biosimilar regulatory approval in the prior year period.

#### Research and Development

Generics R&D expenses for the nine months ended September 30, 2023 decreased 23.8% compared to the prior year period primarily due to reduced project spend of $13.5 million, decreased in-licensing and upfront milestone payments of $2.6 million and operating efficiencies in our infrastructure, including reduced employee compensation costs.

#### Insurance Recoveries for Property Losses and Associated Expenses

During the nine months ended September 30, 2022, insurance recoveries of $1.9 million associated with property damage and inventory losses were received and recorded in insurance recoveries for property losses and associated expenses. Refer to *Note 23. Insurance Recoveries for Property Losses and Associated Expenses.*

#### (Credit) Charges Related to Legal Matters, Net

For the nine months ended September 30, 2023, credit related to legal matters, net was $2.9 million, primarily comprised of $10 million from the settlement of patent infringement matters, partially offset by $4.1 million of charges associated with prescription opioid litigation and a $3.0 million charge for the settlement of a customer claim. For the nine months ended September 30, 2022, charges related to legal matters, net was $2.4 million, primarily comprised of $1.2 million for the settlement of employment claims and other legal proceedings. Refer to *Note 19. Commitments and Contingencies* for additional information.

#### Other Operating Income

Other operating income for the nine months periods ended September 30, 2023 and 2022 was comprised of income earned from the India Production Linked Incentive Scheme for the Pharmaceutical Sector. Refer to *Note 6. Government Grants* for additional information.

### Specialty

The following table sets forth results of operations for our Specialty segment for the nine months ended September 30, 2023 and 2022 (in thousands):

|  | Nine Months Ended September 30, 2023 | 2022 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $285,976 | $271,571 | $14,405 | 5.3% |
| Cost of goods sold | 135,254 | 130,363 | 4,891 | 3.8% |
| **Gross profit** | 150,722 | 141,208 | 9,514 | 6.7% |
| Selling, general and administrative | 67,894 | 69,772 | (1,878) | (2.7)% |
| Research and development | 19,294 | 24,399 | (5,105) | (20.9)% |
| Intellectual property legal development expenses | 110 | 77 | 33 | 42.9% |
| Acquisition, transaction-related and integration expenses | — | 47 | (47) | (100.0)% |
| Restructuring and other charges | 1,013 | — | 1,013 | nm |
| Change in fair value of contingent consideration | (787) | (1,495) | 708 | (47.4)% |
| **Operating income** | $63,198 | $48,408 | $14,790 | 30.6% |

nm - not meaningful

#### Net Revenue

Specialty net revenue for the nine months ended September 30, 2023 increased 5.3% compared to the prior year period, primarily driven by 30.7% growth in Unithroid® and a 0.8% increase in Rytary®, which was negatively impacted by Medicare rebates associated with the Inflation Reduction Act of approximately $5.5 million. Excluding these rebates, net revenues of Rytary® increased 5.0%

#### Cost of Goods Sold and Gross Profit

Specialty cost of goods sold for the nine months ended September 30, 2023 increased 3.8% as compared to the prior year period, primarily due to an increase in net revenue. Specialty gross profit as a percentage of net revenue increased to 52.7% for the nine months ended September 30, 2023 as compared to 52.0% in the prior year period due to favorable product mix.

#### Selling, General, and Administrative

Specialty SG&A expense for the nine months ended September 30, 2023 decreased 2.7% as compared to the prior year period primarily due to a decrease in third-party marketing spend for our promoted products.

#### Research and Development

Specialty R&D expenses for the nine months ended September 30, 2023 decreased 20.9% as compared to the prior year period primarily due to a decrease in in-licensing and upfront milestone payments of $4.5 million.

### AvKARE

The following table sets forth results of operations for our AvKARE segment for the nine months ended September 30, 2023 and 2022 (in thousands):

|  | Nine Months Ended September 30, 2023 | 2022 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| **Net revenue** | $382,286 | $298,066 | $84,220 | 28.3% |
| Cost of goods sold | 318,626 | 256,626 | 62,000 | 24.2% |
| **Gross profit** | 63,660 | 41,440 | 22,220 | 53.6% |
| Selling, general and administrative | 41,268 | 39,361 | 1,907 | 4.8% |
| **Operating income** | $22,392 | $2,079 | $20,313 | nm |

nm - not meaningful

#### Net Revenue

AvKARE net revenue for the nine months ended September 30, 2023 increased 28.3% as compared to the prior year period, primarily driven by growth in our distribution and government label channels resulting from growth in new product introductions.

#### Cost of Goods Sold and Gross Profit

AvKARE cost of goods sold for the nine months ended September 30, 2023 increased 24.2% as compared to the prior year period, and gross profit as a percentage of net revenue increased to 16.7% for the nine months ended September 30, 2023 from 13.9% in the prior year period, primarily due to the increase in sales through our higher margin government channel including higher margin new product introductions and a lower inventory provision.

#### Selling, General and Administrative

AvKARE SG&A expense for the nine months ended September 30, 2023 increased 4.8% compared to the prior year period primarily due to higher employee compensation.

### Liquidity and Capital Resources

Our primary source of liquidity is cash generated from operations, available cash on hand, and borrowings under debt financing arrangements, including $275.9 million of available capacity, as of September 30, 2023, on our New Revolving Credit Facility, as defined in *Note 16. Debt* in our 2022 Annual Report on Form 10-K. Refer to *Note 16. Debt* in our 2022 Annual Report on Form 10-K for additional information on our debt. As of September 30, 2023, there was also $22.0 million of available capacity under the Amended Rondo Revolving Credit Facility. During October 2023, we repaid $6.0 million of borrowings from the Amended Rondo Revolving Credit Facility. We believe these sources are sufficient to fund our planned operations, meet our interest and contractual obligations, including acquisitions, and provide sufficient liquidity over the next 12 months from the date of filing of this Form 10-Q. However, our ability to satisfy our working capital requirements and debt obligations will depend upon economic conditions, our ability to negotiate and maintain satisfactory terms under our borrowing and debt facilities in the future, and demand for our products, which are factors that may be out of our control. On October 24, 2023, we launched refinancing syndication efforts for the Amended Term Loan with a number of financial institutions, including TPG Capital. We target to close on the refinancing during the fourth quarter of 2023.

We estimate that we will invest approximately $50.0 million to $60.0 million during 2023 for capital expenditures to support and grow our existing operations, primarily related to investments in manufacturing equipment, information technology and facilities.

During the nine months ended September 30, 2023, we prepaid $27.8 million of principal outstanding on the Rondo Term Loan. Over the next 12 months, we expect to make substantial payments, including a $50.0 million payment on January 17, 2024 associated with the Opana ER® antitrust litigation settlement agreements, monthly interest and quarterly principal amounts due for our debt instruments, including our Term Loan and Rondo Term Loan, and contractual payments for leased premises. Refer to *Note 16. Debt* and *Note 18. Leases* in our 2022 Annual Report on Form 10-K and *Note 15. Debt* in this Form 10-Q for additional information on our indebtedness and leases, respectively.

We are party to a tax receivable agreement (“TRA”) that requires us to make cash payments to the Members other than the Company, in respect of certain tax benefits that we may realize or may be deemed to realize as a result of sales or exchanges of Amneal Common Units by the Members prior to the Reorganization. The TRA also requires that we make an accelerated payment to the Members equal to the present value of all future payments due under the agreement upon certain change of control and similar transactions. The Reorganization is not a change of control or similar transaction resulting in an accelerated payment to the Members. As of September 30, 2023, the contingent liability under the TRA was approximately $202.7 million (refer to *Note 7. Income Taxes*). In connection with the Reorganization, the parties have agreed to reduce the Company’s contingent obligation to pay 85% of the tax benefits subject to the TRA to 75% of such tax benefits. The Reorganization reduced the Company’s contingent liability under the TRA subsequent to September 30, 2023. Increases in our tax rate in effect at the time of realization of our taxable income occurring subsequent to September 30, 2023, could result in additional future Amneal tax deductions and obligations to pay 75% of such benefits to the Amneal Members. As a result of the foregoing, our obligations under the TRA could have a substantial negative impact on our liquidity. For further details, refer to *Item 1A. Risk Factors* in our 2022 Annual Report on Form 10-K.

In addition, pursuant to the previous limited liability operating agreement of Amneal, as amended, in connection with any tax period, we were required to make distributions (“Cash Tax Distributions”) to Amneal’s members, on a pro rata basis in proportion to the number of Amneal Common Units held by each member, of cash until each member (other than Amneal) has received an amount at least equal to its assumed tax liability and Amneal has received an amount sufficient to enable it to timely satisfy all of its U.S. federal, state and local and non-U.S. tax liabilities, and meet its obligations pursuant to the TRA. During the nine months ended September 30, 2023 and 2022, we made Cash Tax Distributions of $57.59 million and $9.81 million (net), respectively, to the Members. In connection with the Reorganization, Amneal amended and restated its limited liability company agreement to remove the obligation for Amneal to make tax distributions to its members.

In 2020, we acquired a 65.1% controlling interest in both AvKARE Inc., a Tennessee corporation, now a limited liability company (“AvKARE, LLC”), and Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S”). The sellers of AvKARE, LLC and R&S (the “AvKARE Sellers”) hold the remaining 34.9% interest in the holding company that directly owns the acquired companies (“Rondo”). We attribute 34.9% of the net income or loss associated with Rondo to redeemable non-controlling interests. During the nine months ended September 30, 2023 and 2022, we made cash tax distributions of $10.29 million and $3.32 million, respectively, to the AvKARE Sellers.

As of September 30, 2023, our cash and cash equivalents consist of cash on deposit and highly liquid investments. A portion of our cash flows are derived outside the U.S. As a result, we are subject to market risk associated with changes in foreign exchange rates. We maintain cash balances at both U.S. based and foreign country based commercial banks. At various times during the year, our cash balances held in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation (FDIC). We make our investments in accordance with our investment policy. The primary objectives of our investment policy are liquidity and safety of principal.

### Cash Flows

The following table sets forth our summarized, consolidated cash flows for the nine months ended September 30, 2023 and 2022 (in thousands):

| Cash provided by (used in): | Nine Months Ended September 30, 2023 | 2022 | Increase (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| Operating activities | $209,754 | $88,392 | $121,362 | 137.3% |
| Investing activities | (37,497) | (162,843) | 125,346 | (77.0)% |
| Financing activities | (111,741) | (84,453) | (27,288) | 32.3% |
| Effect of exchange rate changes on cash | (136) | (1,944) | 1,808 | (93.0)% |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $60,380 | $(160,848) | $221,228 | nm |

nm - not meaningful

#### Cash Flows from Operating Activities

Net cash provided by operating activities was $209.8 million for the nine months ended September 30, 2023 as compared to $88.4 million provided by operating activities for the prior year period. The increase in operating cash flows from the prior year period was primarily driven by increased profitability adjusted for non-cash items, a favorable year-over-year working capital comparison and a $29.5 million decrease in cash payments related to the Opana ER® antitrust litigation settlement agreements.

#### Cash Flows from Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2023 was $37.5 million as compared to $162.8 million for the prior year period. The decrease in net cash used in investing activities from the prior year period was primarily due to $84.7 million of cash paid to acquire the baclofen franchise from entities affiliated with Saol International Limited during the prior year period and a decrease in acquisition of intangible assets of $39.3 million.

#### Cash Flows from Financing Activities

Net cash used in financing activities was $111.7 million for the nine months ended September 30, 2023 as compared to $84.5 million for the prior year period. The increase in net cash used in financing activities from the prior year period was primarily due to a $54.7 million increase in tax distributions to non-controlling interests and a decrease in net borrowings under our revolving credit facilities, partially offset by a $44.0 million payment for deferred consideration associated with the acquisitions of Kashiv Specialty Pharmaceuticals, LLC and Puniska Healthcare Pvt. Ltd. in the prior year period and lower prepayments on the Rondo Term Loan. Refer to *Note 15. Debt* in this Form 10-Q and *Note 16. Debt* in our 2022 Annual Report on Form 10-K for details of our debt, including defined terms.

### Commitments and Contractual Obligations

The contractual obligations of the Company are set forth in *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* contained in the Company’s 2022 Annual Report on Form 10-K. As of September 30, 2023, there have been no material changes to the disclosure presented in our 2022 Annual Report on Form 10-K.

### Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2023.

### Critical Accounting Policies and Estimates

For a discussion of the Company’s critical accounting policies and estimates, see *Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations* in our 2022 Annual Report on Form 10-K. There have been no material changes to the disclosures presented in our 2022 Annual Report on Form 10-K.

### Recently Issued Accounting Standards

Recently issued accounting standards are discussed in *Note 2. Summary of Significant Accounting Policies.*

## Market risk

As filed, 198 characters.

There has not been any material change in our assessment of market risk as set forth in *Item 7A. Quantitative and Qualitative Disclosures About Market Risk*, in our 2022 Annual Report on Form 10-K.

## Controls and procedures

As filed, 3,068 characters.

### Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Co-Chief Executive Officers and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2023.

### Changes in Internal Control over Financial Reporting

In July 2023, as part of our ongoing efforts to increase efficiencies, we implemented new software and updated various business processes related to financial statement consolidation and indirect procurement. Except as noted above, there were no changes in internal control over financial reporting which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on the Effectiveness of Controls

Management, including our Co-Chief Executive Officers and Chief Financial Officer, does not expect that our disclosure controls and procedures or our system of internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed or operated, can provide only reasonable, but not absolute, assurance that the objectives of the system of internal control are met. The design of our control system reflects the fact that there are resource constraints, and that the benefits of such control system must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control failures and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the intentional acts of individuals, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part on certain assumptions about the likelihood of future events, and there can be no assurance that the design of any particular control will always succeed in achieving its objective under all potential future conditions.

## Risk factors

As filed, 134 characters.

There have been no material changes to the disclosures presented in our 2022 Annual Report on Form 10-K under *Item 1A. Risk Factors.*

Filed Nov 9, 2023.
Source: SEC EDGAR, the filing index for accession 0001723128-23-000044. Last ingested by Listed: Nov 10, 2026, 02:45 ET. No prices; not investment advice.
